A Community-based Assessment of Skin Care, Allergies, and Eczema
Part of paid clinical trials in Denver, Colorado.
- Sponsor
- Oregon Health and Science University
- Study ID
- NCT03409367
- Status
- Completed
Conditions
- Atopic Dermatitis
- Atopic Disorders
- Atopic Eczema
- Eczema
Eligibility Criteria
- Sex
- ALL
- Age
- 1 Day - 63 Days
- Healthy Volunteers
- Accepted
Interventions
- Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream — OTHERLipid-rich emollient serving as skin barrier
Study Details
Atopic dermatitis (AD) affects over 9 million children in the U.S. and often heralds the development of asthma, food allergy, skin infections and neurodevelopmental disorders. Recent advances identify skin barrier dysfunction to be the key initiator of AD and possibly allergic sensitization. Our central hypothesis is that daily emollient use from birth can prevent the development of AD in a community setting and into newborns unselected for risk. The results of a community-based clinical trial utilizing a pragmatic trial design will be immediately applicable to the population at large and will establish a new standard of care for all newborns.
Key Dates
- Start date
- Jul 16, 2018
- Status verified
- Aug 2025
- Primary completion
- Sep 29, 2023
- Completion
- Jan 31, 2024
Study Design
- Enrollment
- 1,260 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- PREVENTION
Arms
- Experimental: Daily EmollientParent-infant dyads assigned to the intervention arm receive a lipid-rich emollient and educational materials promoting once daily full-body emollient use until the infant is 24 months old. Parents select one of five emollients to be mailed to the dyad's home at enrollment and approximately every six months for the duration of the study. These emollients include (1) CeraVe Healing Ointment, (2) Vaseline, (3) Cetaphil cream, (4) CeraVe cream, and (5) Vanicream.
- No Intervention: Natural SkinParent-infant dyads assigned to the control arm receive educational materials promoting general infant skin care guidelines only and are asked to refrain from emollient use unless dry skin develops (current standard of care guidelines).
Primary Outcome Measure
Provider-diagnosed Atopic Dermatitis [ Time Frame: up to 24 months ]
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Colorado-Denver | Denver | Colorado | 80045 | - |
| Duke University | Durham | North Carolina | 27705 | - |
| Oregon Health & Science University | Portland | Oregon | 97239 | - |
| University of Wisconsin-Madison | Madison | Wisconsin | 53175 | - |
Find similar trials in Denver, CO
Related Studies
- A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisPHASE3 · Enrolling By Invitation · Eli Lilly and Company · Birmingham, Alabama
- A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisPHASE2 · Recruiting · Pfizer · Birmingham, Alabama
- Topical Treatment for Atopic DermatitisRecruiting · Wake Forest University Health Sciences · Winston-Salem, North Carolina
- Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control PopulationRecruiting · Incyte Corporation · Morrisville, North Carolina